The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy-Reference-Cited by-同舟云学术

The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy

Published:2019-12-20 Issue:7 Volume:59 Page:1140-1150
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Omori Yukie¹,Enatsu Sotaro¹,Brnabic Alan J.M.²,Rajan Narayan²,Shih Jin-Yuan³,Kim Joo-Hang⁴,Park Keunchil⁵,Inoue Akira⁶

Affiliation:

1. Eli Lilly Japan K.K.

2. Eli Lilly Australia Pty Ltd

3. National Taiwan University Hospital

4. CHA Bundang Medical Center

5. Samsung Medical Center, Sungkyunkwan University School of Medicine

6. Tohoku University

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/59/7/59_1140/_pdf

Reference29 articles.

1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.

2. 2. Polanski J, Jankowska-Polanska B, Rosinczuk J, Chabowski M, Szymanska-Chabowska A. Quality of life of patients with lung cancer. Onco Targets Ther. 2016; 9: 1023-1028.

3. 3. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11: 39-51.

4. 4. Ignoffo R, Lindfelt T, Lozano E. Novel systemic therapies for advanced non-small-cell lung cancer. J Hematol Oncol Pharm. 2017; 7: 34-43.

5. 5. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384: 665-673.